Protocol

ASCIST: A Phase I Study of Immunotherapy Including Haploidentical NK Cell Infusion Following CD133+Positively-Selected Autologous Hematopoietic Stem Cells In Children With High-Risk Solid Tumors or Lymphomas

Diseases

Stem Cell / Bone Marrow Transplant : high-risk solid tumors and lymphomas

Description

This is a research study investigating the addition of Haploidentical natural killer cell infusion to autologous stem cell transplantation. This will be evaluated in participants with high-risk solid tumors for whom autologous transplantation is indicated.


Objectives


Eligibility

Eligibility criteria, among others, include:

Stem Cell Transplant Recipient:

HAPLO NK Cell DONOR:

For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).


Contact

David Shook, MD

St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-888-226-4343 or 901-595-4055
FAX: 901-595-4011

Referring or consulting physicians only: protocolinfo@stjude.org

For all other inquiries about St. Jude Children's Research Hospital studies: info@stjude.org


The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.